ARDELYX, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
ARDELYX, INC. (ARDX) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $2.08 million as of 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2020-08-06
- 2020-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $2.08M.
- 2020-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $2.08M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2020-06-30 | $2.08M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $2.08M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |